Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Short Acting Beta Agonist · 1 trial · 1 indication
Biologic treatments for asthma will include mepolizumab (anti-Interleukin \[IL\] 5), omalizumab (anti-immunoglobulin E \[IgE\]), and reslizumab (anti-IL5).
| Arm | Type | Description |
|---|---|---|
| Non-drug interventional group | OTHER | All enrolled participants will provide a blood sample, spirometry , and feedback on their severe asthma symptoms via questionnaires, and health related quality of life and burden of illness through response to self-administered questionnaires. No investigational product will be administered to participants. |
| Name | Type | Description |
|---|---|---|
| Short Acting Beta Agonist (SABA) | DRUG | Participants requiring a spirometry measurement will be administered a SABA in a metered dose inhaler (MDI) during the reversibility assessments |
Inclusion Criteria: * At least 12 years of age at study visit. * Participants eligible for enrolment and entry into the study must meet the following definition of severe asthma, which is based on the definition of severe asthma described in the European Respiratory Society/ American Thoracic Socie...
Short Acting Beta Agonist is a small molecule being developed for the treatment of asthma. It is currently in Phase 3 clinical development as an investigational therapy. The drug is intended to address respiratory conditions, specifically asthma, and is being studied in patients aged 12 years and older.
Short Acting Beta Agonist is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker symbol GSK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with asthma.
Short Acting Beta Agonist is currently in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the drug remains under evaluation for the treatment of asthma.
Short Acting Beta Agonist has one completed clinical trial registered under NCT02293265, titled "Cross-sectional Study for Identification and Description of Severe Asthma Patients." This Phase 3 study enrolled 767 participants with asthma across the United States, Australia, Canada, France, Germany, and the United Kingdom.
Short Acting Beta Agonist is not FDA approved. It is an investigational drug currently in Phase 3 clinical development for asthma. The completed clinical trial, NCT02293265, was an uncontrolled, non-randomized study that evaluated patients with severe asthma, but regulatory approval has not been granted.